Hua Medicine Reports Single Oral Drug Controls Diabetes for 24 Hours

Hua Medicine of Shanghai announced positive results from a China Phase Ib trial of HMS5552 (sinogliatin) in patients with diabetes. The molecule is a novel oral 4th-generation glucokinase activator (GKA) for Type 2 diabetes that Hua in-licensed from Roche in 2011. In the trial, sinogliatin provided patients with 24-hour glucose control of both fasting plasma glucose and post-meal glucose levels, something that usually requires two separate drugs. Hua expects to start a China Phase II trial and to complete a US Phase I trial of sinogliatin before the end of 2015. More details.... Stock Symbol: (SIX: ROG) Share this with colleagues: // //